The DEA first announced its intent to license private entities to grow Cannabis for FDA approved clinical trials in 2016.
The Drug Enforcement Administration (DEA) is proposing to amend its regulations to comply with the requirements of the Controlled Substances Act, including consistency with treaty obligations, in order to facilitate the cultivation of "marihuana" for research and other licit purposes, according to the Federal Register.
"Specifically, this proposed rule would amend the provisions of the regulations governing applications by persons seeking to become registered with DEA to grow 'marihuana' as bulk manufacturers and add provisions related to the purchase and sale of this 'marihuana' by DEA."
Click here to read the complete article
Sara Brittany Somerset ~ Forbes.com ~
